





DIMA Highlights

Innovations in Therapeutic Antibody Discovery and Functional Membrane Protein Production

DIMA Single B mAb Development Platform



Pre-validated B Cell Libraries for Drug Targets



- 1. High Efficiency: Obtain up to 10,000 positive IgG sequences from each immunized rabbit.
- 2. High Diversity: Immunize at least 5 rabbits for each drug target to ensure IgG sequence diversity.
- 3. High Speed: Obtain validated IgG sequences in as little as 20 days.

5000+ Prevalidated IgG Sequences with Global Licensing Options **500+** Druggable Targets

No Upfront

No Waiting

No Risk

- Immediate Testing (Pre-clinical Validation Data Package available)
- Functional evaluation data on different modality platforms (CAR-T, ADC, BsAb, etc.)
- Mammalian Cell Display Based Antibody Engineering Platform for lead Optimization (Humanization, Affinity Maturation, PTM Risk Removal)
- Complete Solutions for Multi-pass Transmembrane Proteins (Nanodisc, VLP, MNP, Exosome, ECD)

GPRC5D


GPR75

CDH17


Discovery of ADC Lead Molecules

- Off-the-shelf Proteins & Lead mAbs
- Prevalidated B Cell Libraries
- Anti-payload and Anti-linker mAbs
- Antibody Internalization Assays
- Custom ADC Projects

Discovery of ADC Lead Molecules



Lead Molecule Epitope Binning



Human DLL3 ECD

Hot pre-validated Lead mAbs against ADC Targets



Anti-Payload/Linker Rabbit mAb

EC50 of anti-Eribulin mAb binding to

IgG-Eribulin: 1.012 ng/mL.

| Target | sku | Product name |
|----------|-----------|---|
| MMAE | DME101003 | Anti-MMAE antibody(8B4); Rabbit mAb |
| MMAE | DME101004 | Anti-MMAE antibody(8C4); Rabbit mAb |
| MMAE | DME101005 | Anti-MMAE antibody(9C4); Rabbit mAb |
| MMAE | DME101006 | Anti-MMAE antibody(11B2); Rabbit mAb |
| MMAE | DME101007 | Anti-MMAE antibody(11C8); Rabbit mAb |
| SN38 | DME101020 | Anti-SN38 antibody(1G1); Rabbit mAb |
| Dxd | DME101024 | Anti-Dxd antibody(1A1); Rabbit mAb |
| Dxd | DME101025 | Anti-Dxd antibody(1A5); Rabbit mAb |
| Dxd | DME101026 | Anti-Dxd antibody(1A12); Rabbit mAb |
| Dxd | DME101027 | Anti-Dxd antibody(1E6); Rabbit mAb |
| Eribulin | DME101047 | Anti-Eribulin antibody(2E4); Rabbit mAb |
| Eribulin | DME101048 | Anti-Eribulin antibody(3E2); Rabbit mAb |
| Eribulin | DME101049 | Anti-Eribulin antibody(3G1); Rabbit mAb |
| Eribulin | DME101050 | Anti-Eribulin antibody(3G5); Rabbit mAb |
| DM1 | DME101062 | Anti-DM1 antibody(14E3); Rabbit mAb |
| CL2A | DME101021 | Anti-CL2A(ADC linker) antibody(1H6); Rabbit mAb |
| CL2A | DME101022 | Anti-CL2A(ADC linker) antibody(1G9); Rabbit mAb |
| CL2A | DME101023 | Anti-CL2A(ADC linker) antibody(1H2); Rabbit mAb |

MMAE SN38 Dxd ELISA assay to evaluate Anti-MMAE antibody 0.2µg Human IgG-MMAE per well 4.0 3.0 3.0 3.5 Mean Abs.(OD450) Mean Abs.(OD450) Mean Abs.(OD450) 0.5 EC50 of anti-MMAE mAb binding to EC50 of anti-SN38 mAb binding to EC50 of anti-Dxd mAb binding to IgG-MMAE: 2.274 ng/mL. IgG-SN38: 11.39 ng/mL. IgG-Dxd: 3.447 ng/mL. **Eribulin** CL2A (ADC linker) DM1 ELISA assay to evaluate Eribulin-Antibod Mean Abs.(OD450) Mean Abs.(OD450) Mean Abs.(OD450) 2.0 2.0 1.5 1.5

EC50 of anti-DM1 mAb binding to

BSA-DM1: 2.110 ng/mL.


EC50 of anti-CL2A mAb binding to


IgG-CL2A: 2.801 ng/mL.

DiTag™ IgG labeling reagents

| | Catalog No. | Product Description | |
|---|-------------|---|--|
| | AME100001 | DiTag™ pH sensitive IgG labeling reagent | |
| AME100002 DiTag™ pH sensitive IgG labeling reagent plus | | DiTag™ pH sensitive IgG labeling reagent plus | |
| | AME100003 | DiTag™ MMAE IgG labeling reagent | |


pH-Sensitive lgG Labeling Reagents






The fluorescent signal is anti-GPRC5D ADC BMK antibody dependent.


Payload Conjugated lgG Labeling Reagents






Cell inhibition detected by CCK8 method. B7H3 ADC is labeled with DiTag™ MMAE IgG labeling reagent (Cat. No. AME100003)

Discovery of CAR-T Lead Molecules




In vivo efficacy evaluation of the NSG mouse multiple myeloma model.




DiLibrary™: Mammalian Cell Display **Based Antibody Engineering Technology**

1. The design:



2. A natural screening system to fish out molecules with better developability:




Structurally and chemically unstable molecules can be cleared out through mammalian cell internal quality control system.

DiLibrary™ applications: **Antibody affinity maturation**

CDR3 focused mutagenesis Sufficient library diversity CDR1 CDR3

Al optimized mutagenesis library





Case study:

Affinity maturation for CCR8 therapeutic antibody (WT)

| | | Ka(M-1s-1) | Kd(s-1) | KD(M) | Rmax(RU) | Chi2(RU2) |
|--------|-----------|------------|----------|----------|----------|-----------|
| Uniman | WT | 2.82E+05 | 1.49E-02 | 5.26E-08 | 24.5 | 0.3697 |
| Human | Variant 1 | 1.10E+05 | 7.22E-05 | 6.58E-10 | 73.0 | 0.9563 |


| | | | Ka(M-1s-1) | Kd(s-1) | KD(M) | Rmax(RU) | Chi2(RU2) |
|--|------|-----------|------------|----------|----------|----------|-----------|
| | Cyno | WT | 7.56E+04 | 4.35E-05 | 5.75E-10 | 24.3 | 0.739 |
| | | Variant 1 | 1.21E+06 | 2.27E-04 | 1.88E-10 | 55.2 | 0.7985 |






100-fold increase of affinity with only one amino acid mutation at each of LCDR3 and HCDR3.

DiLibrary™ applications: **Antibody Humanization**



Human IgG FR germline library



Case study:

Humanization of Anti-BCMA rabbit monoclonal antibody

| Analyte | Ka (1/Ms) | Kd (1/s) | KD (nM) | Rmax (RU) |
|-------------|-----------|-----------|---------|-----------|
| Rabbit BCMA | 4.3884E+4 | 1.1750E-5 | 0.267 | 65.3 |
| Hu-BCMA1 | 3.1023E+4 | 4.3530E-6 | 0.14 | 105.2 |
| Hu-BCMA2 | 2.8604E+4 | 4.5480E-6 | 0.159 | 78.9 |
| Hu-BCMA3 | 6.4527E+4 | 1.0250E-6 | 0.015 | 81.3 |
| Hu-BCMA4 | 3.3508+4 | 1.9060E-6 | 0.056 | 92.1 |

Comparing with parental rabbit IgG, the humanized antibody (Hu-BCMA3) exhibits 18-fold increase on binding affinity to its target.

Biosimilar Reference Antibodies


Wide Coverage of Hot **Drug Targets & Popular** Biosimilars

Validated with In-House Recombinant **Proteins & Cells**


PE & Biotin Labeling for **Versatile Applications**

Case Study

Anti-PD1 (pembrolizumab biosimilar) mAb ELISA 0.2 ug of Human PD1, mFc-His Tagged protein per well



Anti-PD-1 pembrolizumab biosimilar (Cat.No.BME100006) binds pre-coated PD1 ELISA plate (0.24-6.49 ng/ml).




HEK293 cells expressing PD1 (A) or irrelevant protein (B) were stained with Anti-PD-1 pembrolizumab biosimilar (Cat# BME100006) 1µg/ml and Alexa 488-secondary.

Biotinylated




Biotinylated Anti-STEAP1 Vandortuzumab biosimilar (Cat.No.BME100188B) mAb on SNU-5 cell line (Blue histogram) or 293T (Red histogram).

PE-conjugated



PE-conjugatedAnti-Trop2 sacituzumab biosimilar (Cat.No.BME100023P) on T-47D cell line (Blue histogram) or 293T (Red histogram).




Anti-CLDN18.2 zolbetuximab biosimilar (Cat.No.BME100075P) on AGS-CLDN18.2 stable expression cell line (Blue histogram) or 293T (Red histogram).

Featured Products


| Target | sku | Product name | |
|--------|-----------|---|--|
| TIGIT | BME100026 | Anti-TIGIT (tiragolumab biosimilar) mAb | |
| LILRB4 | BME100237 | Anti-LILRB4(MK-0482 biosimilar) mAb | |
| GPC3 | BME100147 | Anti-GPC3(Hu9F2) mAb | |
| TSHR | BME100079 | Anti-TSHR (M22) mAb | |
| MAPT | BME100498 | Anti-MAPT(etalanetug biosimilar) mAb | |
| GPC3 | BME100083 | Anti-GPC3(codrituzumab biosimilar) mAb | |
| CLDN1 | BME100750 | Anti-CLDN1(eclutatug biosimilar) mAb | |

For more in-stock reference antibodies or custom services, please visit the DIMA website at https://www.dimabio.com/biosimilar-eference-antibodies or contact info@dimabio.com for more details.


Gene Overexpression Stable Cell Lines



Case Study



Cytotoxicity screening of ADC candidate antibodies using the 293T-DLL3 stable cell line(Cat. No.CEL100039) helps identify antibodies with effective internalization.




Using K562 stable cell lines expressing GPRC5D/BCMA as surrogate tumor cells, co-cultured with CAR-T cells. In this 7-day assay, CAR-T cells undergo four rounds of tumor challenge to assess the cytotoxicity of T cells against these "target cells," thereby evaluating the specificity of T cell-mediated killing and the potential off-target risks.

Featured Products

| Target | Host Cell | sku | Product name |
|----------|-----------|-----------|----------------------------|
| GPRC5D | K562 | CEL100001 | Hu_GPRC5D K562 Cell Line |
| PD-L1 | K562 | CEL100022 | Hu_PD-L1 K562 Cell Line |
| PD-L1 | Jurkat | CEL100023 | Hu_PD-L1 Jurkat Cell Line |
| EGFR | K562 | CEL100005 | Hu_EGFR K562 Cell Line |
| Trop2 | K562 | CEL100030 | Hu_TROP2 K562 Cell Line |
| HER3 | Jurkat | CEL100032 | Hu_HER3 Jurkat Cell Line |
| CD47 | CHO-S | CEL100040 | Hu_CD47 CHO-S Cell Line |
| GPR75 | CHO-S | CEL100092 | Hu_GPR75 CHO-S Cell Line |
| B7-H3 | K562 | CEL100101 | Hu_B7-H3 K562 Cell Line |
| CTLA-4 | CHO-S | CEL100105 | Hu_CTLA-4 CHO-S Cell Line |
| EGFR | K562 | CEL100005 | Hu_EGFR K562 Cell Line |
| VEGFR2 | K562 | CEL100074 | Hu_VEGFR2 K562 Cell Line |
| CD63 | CHO-S | CEL100082 | Hu_CD63 CHO-S Cell Line |
| TIGIT | K562 | CEL100083 | Hu_TIGIT K562 Cell Line |
| GPC3 | K562 | CEL100084 | Hu_GPC3 K562 Cell Line |
| IL21R | K562 | CEL100086 | Hu_IL21R K562 Cell Line |
| VSIG4 | Jurkat | CEL100087 | Hu_VSIG4 Jurkat Cell Line |
| CCR2 | K562 | CEL100088 | Hu_CCR2 K562 Cell Line |
| CDH1 | CHO-S | CEL100089 | Hu_CDH1 CHO-S Cell Line |
| CCR5 | K562 | CEL100090 | Hu_CCR5 K562 Cell Line |
| BTLA | K562 | CEL100091 | Hu_BTLA K562 Cell Line |
| CD123 | K562 | CEL100011 | Hu_CD123 K562 Cell Line |
| CSF1R | K562 | CEL100014 | Hu_CSF1R K562 Cell Line |
| CD25 | K562 | CEL100020 | Hu_CD25 K562 Cell Line |
| ACVR2B | CHO-S | CEL100093 | Hu_ACVR2B CHO-S Cell Line |
| ACVR2A | CHO-S | CEL100094 | M_ACVR2A CHO-S Cell Line |
| ACVR2B | CHO-S | CEL100095 | M_ACVR2B CHO-S Cell Line |
| GPR87 | 293T | CEL100096 | Hu_GPR87 293T Cell Line |
| ACVR2A | CHO-S | CEL100097 | Hu_ACVR2A CHO-S Cell Line |
| GPR75 | CHO-S | CEL100092 | Hu_GPR75 CHO-S Cell Line |
| TSHR | 293T | CEL100098 | Hu_TSHR 293T Cell Line |
| FCRL5 | K562 | CEL100099 | Hu_FCRL5 K562 Cell Line |
| CLDN18.2 | K562 | CEL100100 | Hu_CLDN18.2 K562 Cell Line |
| B7-H3 | K562 | CEL100101 | Hu_B7-H3 K562 Cell Line |
| CD19 | K562 | CEL100102 | Hu_CD19 K562 Cell Line |
| PTPRG | K562 | CEL100103 | Hu_PTPRG K562 Cell Line |

For more in-stock stable cell lines or custom services, please visit the DIMA website at https://www.dimabio.com/gene-overexpression-stable-cell-lines or contact info@dimabio.com for more details.

CDX tissue sections



- Efficient and reliable xenograft models: Covering various human tumor cell lines for model diversity and broad application.
- Precise tissue sections: High-quality slicing ensures tissue structure integrity and accuracy.
- Comprehensive IHC controls: Provide standardized immunohistochemistry control data to optimize antibody screening and validation.











IHC validation Long-term stability

Derived from tumor models

In-stock supply

Customizable services

Partial Product List

| Target | sku | Product name |
|--|-----------|------------------------------------|
| BCMA BTN3A1 CD138 CD147 CD30 CD33 CD38 CD47 CD63 CD99 CS1 GITR GPC1 GPRC5D ICAM-1 MUC1 PDL-1 SELPLG TFRC TIM3 | SLI100001 | M-NSG RPMI-8226 DiSliceX™ SlideSet |
| BTN3A2 CCR1 CD138 CD147 CD164 CD38 CXCR3 GPRC5D KI67 LGALS1 SELPLG | SLI100002 | Balb/C nu MM.1S DiSliceX™ SlideSet |
| AXL CD63 EPCAM LGALS1 | SLI100003 | Balb/C nu PC3 DiSliceX™ SlideSet |
| ADAM9 AFP ALB ANGPTL3 B7H3 CD112 CD24 CDH6 CLDN6 CLU CXADR GPC3 HER3 MSLN PRLR SCF | SLI100004 | Balb/C nu HuH7 DiSliceX™ SlideSet |

For more in-stock tissue sections or custom services, please visit the DIMA website at https://www.dima $bio.com/cdx-tissue-sections-for-ihc-screening\ or\ contact\ info@dimabio.com\ for\ more\ details.$

Solutions for the Full-length Multi-pass **Transmembrane Proteins**

5 Production Platforms

Drug Targets for Cancer Therapy


Function Validated Proteins



VLP



Exosome






Synthetic Nanodisc




Detergent

Synthetic Nanodiscs

Multipass Transmembrane Proteins, Right off the Shelf.




- Largest in-stock selection: 500+ full-length multi-transmembrane proteins, including GPCRs and ion channels, leading globally.
- Maximum transmembrane count: Successfully produced 24-transmembrane full-length proteins, pushing industry limits.
- Comprehensive validation: High purity, solubility, and stability, maintaining native conformation and supporting room-temperature shipping.
- Flexible customization: Personalized protein expression services to meet diverse research needs.




Human SCN5A-Nanodisc, Flag Tag on SDS-PAGE. 24-pass Na+ion channel, cat.

No.FLP100726




The purity of Human SLC7A11 full length protein-synthetic nanodisc is greater than 90% as determined by SEC-HPLC. 12-pass Cystine/glutamate transporter, Cat. No. FLP100048





ELISA analysis using anti-GPRC5D monoclonal antibody (Cat. No. DME100090) and purified human GPRC5D full length protein-synthetic nanodisc, 7-pass GPCR, Cat. No. FLP100011

SPR assay to evaluate GPR75-Strep-Nanodisc



Human GPR75-Nanodisc can bind Anti-GPR75 antibody (DMC100368) with an affinity constant of 5.02 nM as determined in a SPR assay. 7-pass GPCR, cat. No. FLP120031

In-Stock Synthetic Nanodiscs for Multi-Pass Transmembrane Proteins

Featured GPCR Proteins

| Target | Cat. No. | Product name |
|---------|-----------|--|
| ADGRE2 | FLP100090 | Human ADGRE2 full length protein-synthetic nanodisc |
| ADORA2A | FLP100020 | Human ADORA2A full length protein-synthetic nanodisc |
| C5AR1 | FLP100086 | Human C5AR1 full length protein-synthetic nanodisc |
| CB1 | FLP100023 | Human CB1 full length protein-synthetic nanodisc |
| CCR1 | FLP100094 | Human CCR1 full length protein-synthetic nanodisc |
| CCR3 | FLP100075 | Human CCR3 full length protein-synthetic nanodisc |
| CCR4 | FLP100024 | Human CCR4 full length protein-synthetic nanodisc |
| CCR6 | FLP100059 | Human CCR6 full length protein-synthetic nanodisc |
| CCR7 | FLP100060 | Human CCR7 full length protein-synthetic nanodisc |
| CCR8 | FLP100037 | Human CCR8 full length protein-synthetic nanodisc |
| CCR9 | FLP100061 | Human CCR9 full length protein-synthetic nanodisc |
| CXCR1 | FLP100091 | Human CXCR1 full length protein-synthetic nanodisc |
| CXCR2 | FLP100066 | Human CXCR2 full length protein-synthetic nanodisc |
| CXCR3 | FLP100053 | Human CXCR3 full length protein-synthetic nanodisc |
| CXCR4 | FLP100074 | Human CXCR4 full length protein-synthetic nanodisc |
| CXCR5 | FLP100067 | Human CXCR5 full length protein-synthetic nanodisc |
| CXCR7 | FLP100095 | Human CXCR7 full length protein-synthetic nanodisc |
| F2RL1 | FLP100036 | Human F2RL1 full length protein-synthetic nanodisc |
| FSHR | FLP100047 | Human FSHR full length protein-synthetic nanodisc |
| FZD10 | FLP100052 | Human FZD10 full length protein-synthetic nanodisc |
| GCGR | FLP100085 | Human GCGR full length protein-synthetic nanodisc |
| GPR75 | FLP100031 | Human GPR75 full length protein-synthetic nanodisc |
| GPRC5D | FLP100011 | Human GPRC5D full length protein-synthetic nanodisc |
| HCRTR1 | FLP100099 | Human HCRTR1 full length protein-synthetic nanodisc |
| LGR4 | FLP100072 | Human LGR4 full length protein-synthetic nanodisc |
| LGR5 | FLP100073 | Human LGR5 full length protein-synthetic nanodisc |
| PTGER4 | FLP100097 | Human PTGER4 full length protein-synthetic nanodisc |
| SSTR2 | FLP100013 | Human SSTR2 full length protein-synthetic nanodisc |
| TSHR | FLP100045 | Human TSHR full length protein-synthetic nanodisc |

Discover Your Protein from Our Comprehensive Nanodisc Collection at the Following Website: https://www.dimabio.com/synthetic-nanodisc-membrane-protein

DIMA Products

ADC ASSAY REAGENTS



DRUG TARGET PROTEINS

DIMA MONOCLONAL ANTIBODIES

BIOSIMILAR REFERENCE ANTIBODIES

STABLE DRUG TARGET CELL LINES

DRUG TARGET POSITIVE TISSUE SECTIONS

DIMA Technology Platforms

DiMPro™ Membrane Protein Preparation Platform Single B Monoclonal Antibody Development Platform Mammalian Cell Display Antibody **Engineering Platform** Preclinical Antibody Functional **Evaluation Platform BCMA** CCR8 ROR1

DIMA Biotechnology

Dedicate on immuno-oncology, Perfect with recombinant mAb development

DIMA Biotechnology

